Multiple Sclerosis Treatments: World Market Outlook to 2011

 
   Single User - $500
   Corporate License - $5,990


Loading...
Published Jun 1, 2007 | 110 Pages | Pub ID: KLI1399466

Multiple sclerosis (MS) is a chronic demyelinating CNS disease that causes significant disability in young adults and others. Worldwide, millions of people are affected by multiple sclerosis. Although there is no cure, approved treatments are available to slow the progression of MS and offer improved quality of life.

Kalorama Information's: Multiple Sclerosis Treatments: World Market Outlook to 2011 is one of the few publications to take a detailed look at multiple sclerosis treatment market worldwide, as well as treatments that will be available in the future. The market for these treatments has continued at double-digit growth rates, and this is expected in the near term. This report includes:

  • A Complete Description of MS, its Causes and Symptoms
  • Complete Incidence and Prevalence Statistics For U.S. and Worldwide.
  • Triggers and Risk Factors of MS.
  • Review of Multiple Sclerosis Treatments on the Market
  • Market Size and Forecasts For Treatments to 2011.
  • Issues and Trendsfacing MS treatment
  • New Multiple Sclerosis Treatments in the pipeline.
Kalorama Information's study focuses on the following four treatments:
  • Copaxone
  • Avonex
  • Rebif
  • Betaseron/Betaferon
Additionally, the report includes products which contribute a smaller amount of sales such as Novantrone. Revenues are included for currently marketed products for each of the major pharmaceutical markets - United States, Europe, and Japan. Late stage development projects are discussed in detail with forecasts for potential revenues and anticipated approval dates. Revenues for each segment were generated using dollar and unit sales for each product.

Issues and trends that are critical for the future of MS treatment are discussed in the report:

  • Medicare and Health Insurance Issues
  • NIH Multiple Sclerosis Funding Reduction
  • Stem Cell Controversy and MS
  • Access to Life-Saving Medicine Act and MS
  • Par-3 Discovery
  • Cyclophilin D Regulation
  • Women and MS
  • Pregnancy and MS
  • Alternative Therapies in MS
  • MS and Diabetes
As part of Kalorama's trusted information -gathering process, intensive research into company, trade and medical literature was supplemented by interviews with experts in the multiple sclerosis treatment industry. Interviews make up the source of forecast and market size figures.

The company profiles in this report display the diversity of products and strategies that are being explored in the multiple sclerosis market. These data were obtained from collateral material provided by the company profiled and/or through interviews with company officials. Competitors are primarily comprised of large pharmaceutical companies and biotech leaders such as Bayer Schering Pharma and Biogen IDEC. Company profiles included are:

  • Bayer Schering Pharma AG
  • Biogen IDEC
  • Novartis AG
  • Sanofi-Aventis
  • Merck Serono S.A.
  • TEVA
CHAPTER ONE: EXECUTIVE SUMMARY
  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues an Trends Affecting Market
  • Leading Competitors

CHAPTER TWO: INTRODUCTION

  • Introduction to Multiple Sclerosis
  • Progression of Multiple Sclerosis
  • Relapsing-remitting MS
  • Primary-progressive MS
  • Secondary-progressive MS
  • Progressive-relapsing MS
  • Benign MS
  • Pathogenesis of MS
  • Inflammatory Response and MS
  • Triggers
  • Risk Factors
  • Physical Complications of MS
  • Diagnosing MS
  • Demographics and Statistics

CHAPTER THREE: TREATMENTS FOR MULTIPLE SCLEROSIS

  • Description of Products
  • Copaxone
  • Avonex
  • Rebif
  • Betaferon/Betaseron
  • Tysabri
  • Novantrone
  • Research and Development
  • Late Stage Development
  • Early to Mid Stage Development
  • Phase II Development
  • Phase I Development
  • Preclinical Development and Research
  • Experimental Drugs and Treatments
  • Discontinued Development
  • Market and Competitive Analysis
  • World Market Analysis
  • World Competitive Analysis
  • Markets by World Region
  • U.S. Market
  • Europe Market
  • Japan Market

CHAPTER FOUR: ISSUES AND TRENDS AFFECTING THE MS MARKET

  • Introduction
  • Medicare and Health Insurance Issues
  • NIH MS Funding Reduction
  • Stem Cell Controversy and MS
  • Access to Life-Saving Medicine Act and MS
  • Par-3 Discovery
  • Cyclophilin D Regulation
  • Women and MS
  • Pregnancy and MS
  • Alternative Therapies in MS Treatment
  • MS and Diabetes

CHAPTER FIVE: COMPANY PROFILES

  • Bayer Schering Pharma AG
  • Biogen IDEC
  • Novartis AG
  • Sanofi-Aventis
  • Merck Serono S.A.
  • Teva Pharmaceutical Industries Ltd

APPENDIX: COMPANY NAMES AND ADDRESSES

TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
  • Table 1-1: Multiple Sclerosis Cases in Selected Countries.
  • Table 1-2: The Worldwide Multiple Sclerosis Market 2004-2011
  • Figure 1-1: The Worldwide Multiple Sclerosis Market 2004-2011
CHAPTER TWO: INTRODUCTION
  • Table 2-1: Estimated World Prevalence of Multiple Sclerosis by Selected Countries
  • Figure 2-1: Estimated World Prevalence of Multiple Sclerosis by Selected Countries
  • Table 2-2: World Population by Selected Geographical Region, 2006-2050
  • Figure 2-2: World Population by Selected Geographical Region, 2006-2050
  • Table 2-2: World Population by Selected Countries, 2006
  • Figure 2-3: World Population by Selected Countries, 2006
  • Table 2-3: Estimated World Population by Age, sex and Geographical Region, 2006
  • Figure 2-4: Estimated World Population by Age and Geographical Region, 2006
  • Figure 2-5: Estimated World Population by Sex and Geographical Region, 2006
CHAPTER THREE: TREATMENTS FOR MULTIPLE SCLEROSIS
  • Table 3-1: Currently Available Multiple Sclerosis
  • Treatments (Brand Name, Generic Name, Marketer and Approval Dates)
  • Table 3-2: Estimated World Sales for Leading Products, 2004-2006
  • Figure 3-1: Estimated World Sales for Leading Products, 2006
  • Figure 3-2: Estimated World Sales for Leading Products 2004-2006
  • Figure 3-3: Estimated World Sales for Leading Products, 2006
  • Table 3-3: Multiple Sclerosis Products in Late Stage Development
  • Table 3-4: Multiple Sclerosis Products in Early to Mid-Stage Development
  • Table 3-5: The Worldwide Multiple Sclerosis Market 2004-2011
  • Figure 3-4: The Worldwide Multiple Sclerosis Market 2004-2011
  • Table 3-6: The Worldwide Multiple Sclerosis Market Estimated Revenues and Market Share of Leading Suppliers 2006
  • Figure 3-5: The Worldwide Multiple Sclerosis Market Estimated Market Share by Leading Suppliers 2001
  • Table 3-7: The Worldwide Multiple Sclerosis Market Projected Revenues and Market Share of Leading Suppliers 2011
  • Figure 3-6: The Worldwide Multiple Sclerosis Market Projected Market Share by Leading Suppliers 2011
  • Table 3-8: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2004-2006
  • Figure 3-7: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2004-2006
  • Figure 3-8: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2004
  • Figure 3-9: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2005
  • Figure 3-10: The Worldwide Multiple Sclerosis Market Estimated Products Sales by Geographic Region, 2006
  • Table 3-9: The U.S. Multiple Sclerosis Market Estimated Revenues and Market Share of Leading Suppliers 2006
  • Figure 3-13: The U.S. Multiple Sclerosis Market Projected Market Share by Leading Suppliers 2006
  • Table 3-10: The European Multiple Sclerosis Market Estimated Revenues and Market Share of Leading Suppliers 2006
  • Figure 3-14: The European Multiple Sclerosis Market Projected Market Share by Leading Suppliers 2006
  • Table 3-11: The Japanese Multiple Sclerosis Market Estimated Revenues and Market Share of Leading Suppliers 2006
  • Figure 3-15: The Japanese Multiple Sclerosis Market Projected Market Share by Leading Suppliers 2006
CHAPTER FOUR: ISSUES AND TRENDS AFFECTING THE MS MARKET
  • Table 4-1: NIH Funding By Year